Skip to content

Antibacterial Effect of Miswak Toothpaste Compared to Fluoride Toothpaste

Antibacterial Effect of Miswak Toothpaste Compared to Fluoride Toothpaste in High Caries Risk Patients: Randomized Clinical Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05109299
Enrollment
32
Registered
2021-11-05
Start date
2021-12-01
Completion date
2022-04-30
Last updated
2021-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Caries

Keywords

Antibacterial, streptococcus mutans, miswak, fluoride

Brief summary

Meswak is scientifically formulated herbal toothpaste with pure extract of the Miswak plant 'Salvadore Persica', the famous 'Toothbrush Tree' used for centuries. The astringent and anti-bacterial properties of Meswak helps reduce tooth decay , fight plaque and prevent gum diseases. Miswak Herb is a rare, potent, priceless, wonder herb that delivers incredible Dental Care benefits.

Detailed description

This study is a randomized clinical trial, with parallel study design, 1:1 allocation ratio and superiority framework. The aim of the current trial is to evaluate antibacterial effect miswak toothpaste compared to fluoride toothpaste in high caries risk patients.

Interventions

OTHERMiswak toothpaste

Dabur Meswak is scientifically formulated herbal toothpaste with pure extract of the Miswak plant 'Salvadore Persica'

OTHERFluoride toothpaste

1450 ppm fluoride toothpaste

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 25 Years
Healthy volunteers
No

Inclusion criteria

* High caries risk patients. * At least one carious tooth according to CAT caries risk assessment model. * Patient compliance

Exclusion criteria

* Participant in another trial. * Using another antimicrobial agents since one month of sampling. * Systemic diseases or concomitant medication affecting salivary flow. * Parafunctional habits. * Pregnancy.

Design outcomes

Primary

MeasureTime frameDescription
streptococcus mutans count3 monthsCounting streptococcus mutans, Measurement: Mitis-Salivarius agar plate, Unit: CFUs/mL

Countries

Egypt

Contacts

Primary ContactOmar O Shaalan, PhD
omar.shaalan@dentistry.cu.edu.eg00201122665661

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026